Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (GB:0H8T)
LSE:0H8T
0H8T Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.96 - $5.15
Previous CloseN/A
Volume4.71K
Average Volume (3M)4.14K
Market Cap
$179.15M
Enterprise Value-$42.92M
Total Cash (Recent Filing)$24.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.37
Next Earnings
May 13, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding107,918,820
10 Day Avg. Volume3,882
30 Day Avg. Volume4,141
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.55
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.69
Enterprise Value/Ebitda0.83
Forecast
1Y Price Target
$10.67Price Target Upside542.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Aclaris Therapeutics News
PremiumCompany Announcements
Aclaris Therapeutics Reports 2024 Financial Results
PremiumPre-Earnings
Is ACRS a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsACRS confirmed that clinical trial activities for the Phase 2b of trial of bosakitug in atopic dermatitis have been initiated.
Financial PerformanceACRS has a cash runway into 2028, supporting its operations for several more years.
Strategic PartnershipsThe acquisition of worldwide rights to two in-licensed biologics, BSI-045B and BSI-502, is expected to strengthen Aclaris Therapeutics Inc.'s immunology-focused pipeline.
Bears Say
Market CompetitionBSI-045B is believed to be differentiated from competitors due to its extended residence time, high binding affinity, and promising pharmacological activity.
Pipeline RisksLegacy pipeline programs may generate additional value.
---
Options Prices
Currently, No data available
---
Ownership Overview
29.40% Insiders
4.88% Mutual Funds
0.42% Other Institutional Investors
59.43% Public Companies and Individual Investors
0H8T FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest share price was $0.96 and its highest was $5.15 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $179.15M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 62 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Feb 27, 2025. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.287 by -$0.723.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 107,918,820 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.287. Following the earnings report the stock price went down -3.317%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in GB:0H8T
---
Aclaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (542.77% Upside)
$10.67 (542.77% Upside)
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.73%
12-Months-Change
Fundamentals
Return on Equity
-84.46%
Trailing 12-Months
Asset Growth
10.41%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
0H8T Stock 12 Month Forecast
Average Price Target
$10.67
▲(542.77% Upside)
Technical Analysis
Best Analysts Covering 0H8T
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-35.97%
reiterated a buy rating 3 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -35.97% per trade.
---